FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912374321> ?p ?o ?g. }

• W2912374321 abstract "Melanoma has several clinically and pathologically distinguishable subtypes, which also differ genetically. Mutation patterns vary among different melanoma subtypes, and efficacy of immune-checkpoint inhibitors differs depending on the subtype of melanoma. In spite of the recent revolution of systemic therapies for advanced melanoma, access to innovative agents is still restricted in many countries. This review article aimed to describe the epidemiology and current status of systemic therapies for melanoma in Japan, where melanoma is rare, but access to innovative agents is available. Acral and mucosal melanomas, which are common in Asian populations, predominantly occur in sun-protected areas and share several biological features. Both the melanomas harbor KIT mutation in approximately 15% of the cases; BRAF or NRAS mutation is found in approximately 10–15% of acral melanoma, but these mutations are less frequent in mucosal melanoma. Combined use of BRAF and MEK inhibitors is one of the standards of care for patients with advanced BRAF-mutant melanoma. In patients with melanoma harboring KIT mutation in exon 11 or 13, KIT inhibitors can be a treatment option; however, none of them have been approved in Japan. Immune-checkpoint inhibitors are expected to be less effective against acral and mucosal melanomas because their somatic mutation burden is lower than those in non-acral cutaneous melanomas. A recently completed phase II trial of nivolumab and ipilimumab combination therapy in 30 Japanese patients with melanoma, including seven with acral and 12 with mucosal melanoma, demonstrated an objective response rate of 43%. Regarding oncolytic viruses, canerpaturev (C-REV, also known as HF10) and talimogene laherparepvec (T-VEC) are currently under review in early phase trials. In the adjuvant setting, dabrafenib plus trametinb combination, nivolumab monotherapy, and pembrolizumab monotherapy were approved in July, August, and December 2018 in Japan, respectively. However, most of the adjuvant phase III trials excluded patients with mucosal melanoma. A phase III trial of adjuvant therapy with locoregional interferon (IFN)-β versus surgery alone is ongoing in Japan (JCOG1309, J-FERON), in which IFN-β is injected directly into the site of the primary tumor postoperatively, so that it would be drained through the untreated lymphatic route to the regional node basin. After the recent approval of these new agents, the JCOG1309 trial will be revised to focus on patients with stage II disease. In conclusion, acral and mucosal melanomas have been treated based on the available medical evidence for the treatment of non-acral cutaneous melanomas. Considering the differences in genetic backgrounds and therapeutic efficacy of immunotherapy, specialized therapeutic strategies for these subtypes of melanoma should be established in the future." @default.
• W2912374321 created "2019-02-21" @default.
• W2912374321 creator A5001893646 @default.
• W2912374321 creator A5047984722 @default.
• W2912374321 date "2019-01-01" @default.
• W2912374321 modified "2023-10-05" @default.
• W2912374321 title "Targeted Therapy and Immunotherapy for Melanoma in Japan" @default.
• W2912374321 cites W1147117258 @default.
• W2912374321 cites W1585375233 @default.
• W2912374321 cites W1828940258 @default.
• W2912374321 cites W1950829641 @default.
• W2912374321 cites W1963976650 @default.
• W2912374321 cites W1965370740 @default.
• W2912374321 cites W1989121777 @default.
• W2912374321 cites W2015682571 @default.
• W2912374321 cites W2017095180 @default.
• W2912374321 cites W2019496774 @default.
• W2912374321 cites W2027891368 @default.
• W2912374321 cites W2034248634 @default.
• W2912374321 cites W2070825440 @default.
• W2912374321 cites W2079641245 @default.
• W2912374321 cites W2096223992 @default.
• W2912374321 cites W2096387850 @default.
• W2912374321 cites W2097691839 @default.
• W2912374321 cites W2097995306 @default.
• W2912374321 cites W2099289479 @default.
• W2912374321 cites W2103152130 @default.
• W2912374321 cites W2109274792 @default.
• W2912374321 cites W2111404068 @default.
• W2912374321 cites W2112121482 @default.
• W2912374321 cites W2112403746 @default.
• W2912374321 cites W2119787454 @default.
• W2912374321 cites W2121545342 @default.
• W2912374321 cites W2123363005 @default.
• W2912374321 cites W2128035403 @default.
• W2912374321 cites W2128542677 @default.
• W2912374321 cites W2130723808 @default.
• W2912374321 cites W2136474966 @default.
• W2912374321 cites W2143923888 @default.
• W2912374321 cites W2147474070 @default.
• W2912374321 cites W2152897456 @default.
• W2912374321 cites W2156266404 @default.
• W2912374321 cites W2160766792 @default.
• W2912374321 cites W2164130643 @default.
• W2912374321 cites W2166262263 @default.
• W2912374321 cites W2320786076 @default.
• W2912374321 cites W2336695065 @default.
• W2912374321 cites W2342956596 @default.
• W2912374321 cites W2412250098 @default.
• W2912374321 cites W2473956396 @default.
• W2912374321 cites W2491982852 @default.
• W2912374321 cites W2515516401 @default.
• W2912374321 cites W2519469881 @default.
• W2912374321 cites W2529373149 @default.
• W2912374321 cites W2553340100 @default.
• W2912374321 cites W2557238488 @default.
• W2912374321 cites W2560367415 @default.
• W2912374321 cites W2572174216 @default.
• W2912374321 cites W2592369722 @default.
• W2912374321 cites W2594274861 @default.
• W2912374321 cites W2594529508 @default.
• W2912374321 cites W2600124489 @default.
• W2912374321 cites W2611187032 @default.
• W2912374321 cites W2611270905 @default.
• W2912374321 cites W2614056985 @default.
• W2912374321 cites W2650204451 @default.
• W2912374321 cites W2733884328 @default.
• W2912374321 cites W2736167445 @default.
• W2912374321 cites W2747107882 @default.
• W2912374321 cites W2748716584 @default.
• W2912374321 cites W2752210999 @default.
• W2912374321 cites W2752227448 @default.
• W2912374321 cites W2753432434 @default.
• W2912374321 cites W2753466295 @default.
• W2912374321 cites W2762638624 @default.
• W2912374321 cites W2770760027 @default.
• W2912374321 cites W2788938550 @default.
• W2912374321 cites W2791686077 @default.
• W2912374321 cites W2793817570 @default.
• W2912374321 cites W2797309423 @default.
• W2912374321 cites W2801342700 @default.
• W2912374321 cites W2806357747 @default.
• W2912374321 cites W2810292296 @default.
• W2912374321 cites W2890146531 @default.
• W2912374321 cites W2890383583 @default.
• W2912374321 cites W2891205725 @default.
• W2912374321 cites W2896253897 @default.
• W2912374321 cites W2896600825 @default.
• W2912374321 cites W2899505264 @default.
• W2912374321 cites W2901290714 @default.
• W2912374321 doi "https://doi.org/10.1007/s11864-019-0607-8" @default.
• W2912374321 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6344396" @default.
• W2912374321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30675668" @default.
• W2912374321 hasPublicationYear "2019" @default.
• W2912374321 type Work @default.
• W2912374321 sameAs 2912374321 @default.
• W2912374321 citedByCount "68" @default.
• W2912374321 countsByYear W29123743212019 @default.
• W2912374321 countsByYear W29123743212020 @default.
• W2912374321 countsByYear W29123743212021 @default.

• next